Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.3260
-0.03-7.28%
At close: -
$0.3298
0.003801.17%
After Hours: 7:43 PM EDT
Comments
Loading...
Passage Bio Analyst Ratings and Price Targets | NASDAQ:PASG | Benzinga
Passage Bio Inc has a consensus price target of $7.29 based on the ratings of 7 analysts. The high is $13 issued by Canaccord Genuity on November 14, 2024. The low is $4 issued by Wedbush on November 29, 2024. The 3 most-recent analyst ratings were released by Chardan Capital, Chardan Capital, and Wedbush on June 24, 2025, March 4, 2025, and November 29, 2024, respectively. With an average price target of $5.33 between Chardan Capital, Chardan Capital, and Wedbush, there's an implied 1517.14% upside for Passage Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
Wedbush
Canaccord Genuity
Rodman & Renshaw
Raymond James
1calculated from analyst ratings
Analyst Ratings for Passage Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2025 | Buy Now | 1719.28% | Chardan Capital | Geulah Livshits49% | $6 → $6 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | 1719.28% | Chardan Capital | Geulah Livshits49% | $7 → $6 | Maintains | Buy | Get Alert |
| 11/29/2024 | Buy Now | 1112.86% | Wedbush | Yun Zhong39% | → $4 | Assumes | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | 2022.5% | Chardan Capital | Geulah Livshits49% | $7 → $7 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 3841.78% | Canaccord Genuity | Whitney Ijem56% | $13 → $13 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 3841.78% | Canaccord Genuity | Whitney Ijem56% | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | 2022.5% | Rodman & Renshaw | — | → $7 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 3841.78% | Canaccord Genuity | Whitney Ijem56% | $14 → $13 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 4145% | Canaccord Genuity | Whitney Ijem56% | → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/21/2023 | Buy Now | 4145% | Canaccord Genuity | Whitney Ijem56% | $8 → $14 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | 1416.07% | Raymond James | Danielle Brill41% | $9 → $5 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | 2628.93% | Chardan Capital | Geulah Livshits49% | $11 → $9 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 2628.93% | Raymond James | Danielle Brill41% | $10 → $9 | Maintains | Outperform | Get Alert |
| 12/15/2022 | Buy Now | 3235.35% | Chardan Capital | Geulah Livshits49% | $18 → $11 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 3235.35% | Guggenheim | Debjit Chattopadhyay53% | $13 → $11 | Maintains | Buy | Get Alert |
| 11/11/2022 | Buy Now | 1416.07% | Citigroup | Neena Bitritto-Garg58% | $7 → $5 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | 2325.71% | Canaccord Genuity | Whitney Ijem56% | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Passage Bio (PASG) stock?
The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on June 24, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a possible 1719.28% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Passage Bio (PASG)?
The latest analyst rating for Passage Bio (NASDAQ:PASG) was provided by Chardan Capital, and Passage Bio maintained their buy rating.
When was the last upgrade for Passage Bio (PASG)?
There is no last upgrade for Passage Bio
When was the last downgrade for Passage Bio (PASG)?
There is no last downgrade for Passage Bio.
When is the next analyst rating going to be posted or updated for Passage Bio (PASG)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on June 24, 2025 so you should expect the next rating to be made available sometime around June 24, 2026.
Is the Analyst Rating Passage Bio (PASG) correct?
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $6.00 to $6.00. The current price Passage Bio (PASG) is trading at is $0.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
